Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + anti-HER2 therapy + aromatase inhibitor versus anti-HER2 therapy + endocrine therapy or taxane chemotherapy in HR-positive HER2-positive recurrent/metastatic breast cancer
ChiCTR2100051512Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dalpiciclib, trastuzumab and pertuzumab in breast cancer (3 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Progression-free survival. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100051512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051512.